Clinical trials: Rejection Acute Renal
Acute Rejection, Renal Transplantation
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
The hypothesis of this study is that lymphocyte depletion by Campath-1H and rituximab will obviate the need for long-term calcineurin inhibitors in renal transplantation.
- Trial name
- NCT00579592
- Testing
- Campath-1H, rituximab, myfortic
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
Cf-DNA Assay During Treatment of Acute Rejection
The objective of this study is to determine whether cell-free DNA (cf-DNA) measurement can be used as a biomarker for successful treatment of an acute rejection (AR) episode after kidney transplantation.
- Conditions
- Kidney Transplant Failure and Rejection, Kidney Transplant; Complications, Kidney Transplant Rejection, Transplant; Complication, Rejection
- Trial name
- NCT04019353
- Testing
- cf-DNA Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Acute Graft Rejection, Renal Failure Chronic Requiring Dialysis
Kidney Transplant Failure
Primary Hypotheses: 1. Among patients who retain the failed kidney transplant, those who continue immunosuppressant medication will have more deaths than patients who discontinue these drugs 2.
- Trial name
- NCT01296061
- Where
- Canada
- Volunteers
- 270 people
- Sponsor
- Ottawa Hospital Research Institute
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Microvascular Inflammation - MVI in Kindey Transplant Recipients
DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)
The DARA-MVI Study is a prospective, randomized, controlled, open-label trial designed to evaluate the effect of daratumumab on microvascular inflammation (MVI) in kidney transplant recipients with C4d-negative biopsies.
- Trial name
- DARA-MVI (NCT07274462)
- Testing
- DARATUMUMAB (DARZALEX®), Observation (Standard Care)
- Where
- Slovakia
- Volunteers
- 20 people
- Sponsor
- University Hospital, Martin
Acute Rejection of Renal Transplant, Renal Graft Loss
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients
Mycophenolate mofetil (MMF) decreases the risk of acute rejection and is associated with improved graft survival in renal transplant recipients.
- Trial name
- NCT01496703
- Testing
- no intervention, this is an observational retrospective trial
- Where
- Belgium
- Volunteers
- 749 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Transplantation
HLA-DQ in Acute Kidney Transplantation Rejection
Study the impact of HLA-DQ mismatch on acute rejection of Kidney transplantation
- Trial name
- NCT03896919
- Testing
- HLA-DQ by luminex technology in kidney transplantation
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Kidney Transplantation, Chronic Kidney Disease
Calcineurin Free Immunosuppression in Renal Transplant Recipients
The main purpose of this study is to obtain preliminary information on the efficacy, safety and cost of two regimens, Rapamycin / MMF / steroid therapy and Cyclosporine A Neoral / MMF / steroid therapy, used in the prevention of…
- Trial name
- NCT00812123
- Testing
- Sirolimus, Cyclosporine A, Prednisone
- Where
- Switzerland
- Volunteers
- 127 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN)
Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients
Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term.
- Conditions
- Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
- Trial name
- Mini-Kidney (NCT01531257)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
A multicenter clinical study comparing event-free survival at 6 months after transplant between Thymoglobulin-treated and Simulect-treated adult kidney transplant patients.
- Conditions
- Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
- Trial name
- NCT00235300
- Testing
- Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 240 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Transplantation
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.
- Trial name
- TAXI (NCT00682292)
- Testing
- Thymoglobulin (ATG), Daclizumab
- Where
- France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Lille
Kidney Transplant, Delayed Graft Function
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in…
- Trial name
- RAPA (NCT00931255)
- Testing
- Tacrolimus, Sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Kidney Injury, Kidney Failure
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure.
- Conditions
- Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute
- Trial name
- STAART (NCT05747053)
- Testing
- AlloSure, PAXGene
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- George Washington University
Acute (Cellular) Renal Allograft Rejection
Single Dose rATG for Renal Allograft Rejection
Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous…
- Trial name
- NCT02102854
- Testing
- rATG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Transplantation
Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00556257
- Testing
- Cyclosporine, CP-690-,550
- Sponsor
- Pfizer
Kidney Transplant Rejection, Kidney Transplant; Complications
Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients
Demonstrate that low dose (3 mg/kg total ) rATG (thymoglobulin) has similar efficacy (delayed graft function, slow graft function, biopsy proven acute rejection episodes, infections, hospitalizations, adverse events, graft loss…
- Trial name
- NCT03006419
- Testing
- Basiliximab, Thymoglobulin
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Kidney Transplant Rejection, Skin Graft
Multi Center Observation of Sentinel Skin Graft for Detecting Acute Rejection After Renal Transplantation
The purpose of this study was to explore the accuracy of sentinel skin grafts from the same donor source in diagnosing renal allograft rejection, and to provide new ideas and options for the later clinical diagnosis of renal…
- Trial name
- NCT05600634
- Testing
- Skin allotransplantation
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Kidney Transplantation
Effect of BM-MSCs on Chronic AMR After Kidney Transplantation
This study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR) after kidney transplantation.
- Trial name
- NCT02563340
- Testing
- BM-MSCs, Desensitization therapy (PP, IVIG, rituximab or Bortezomib)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University